Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 19/20 | 1.00 |
| ▸ | NSD2 | O96028 | 3/20 | 1.00 |
| ▸ | NSD3 | Q9BZ95 | 3/20 | 1.00 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 1.00 |
| ▸ | EZH2 | Q15910 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.93 |
| ▸ | KDM1A | O60341 | 1/20 | 0.93 |
| ▸ | MTOR | P42345 | 1/20 | 0.93 |
| ▸ | RAB9A | P51151 | 1/20 | 0.93 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351415 | 0.97 | EHMT2 (1.00) | EHMT2NSD2NSD3EHMT1EZH2 | |
| SCHEMBL366593 | 0.97 | EHMT2 (1.00) | EHMT2NSD2NSD3EHMT1EZH2 | |
| Hydrochloric Acid SCHEMBL2595237 | 0.96 | EHMT2 (1.00) | EHMT2NSD2NSD3EHMT1EZH2 | |
| Hydrochloric Acid SCHEMBL20535174 | 0.96 | EHMT2 (1.00) | EHMT2NSD2NSD3EHMT1EZH2 | |
| Hydrochloric Acid SCHEMBL29849313 | 0.96 | EHMT2 (1.00) | EHMT2NSD2NSD3EHMT1EZH2 | |
| Water SCHEMBL21610936 | 0.96 | EHMT2 (0.98) | EHMT2NSD2NSD3EHMT1EZH2 | |
| Hydrochloric Acid SCHEMBL15668608 | 0.95 | EHMT2 (0.98) | EHMT2NSD2NSD3EHMT1EZH2 | |
| SCHEMBL15280252 | 0.95 | EHMT2 (1.00) | EHMT2NSD2NSD3EHMT1EZH2 | |
| SCHEMBL20016196 | 0.93 | DNMT3A (1.00) | EHMT2NSD2NSD3EHMT1EZH2 | |
| SCHEMBL15280410 | 0.93 | EHMT2 (0.98) | EHMT2NSD2NSD3EHMT1EZH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150259649-A1 | CELLULAR COMPOSITIONS USED TO RESTORE STEM CELL OR PROGENITOR CELL FUNCTION AND METHODS RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-09-17 | — | — | US | claimed |
| US-20140294764-A1 | COMPOUNDS AND COMPOSITIONS USED TO EPIGENETICALLY TRANSFORM CELLS AND METHODS RELATED THERETO | ISTITUTO PASTEUR - FONDAZIONE CENCI BOLOGNETTI (IT) | 2014-10-02 | — | — | US | claimed |
| WO-2014074517-A1 | CELLULAR COMPOSITIONS USED TO RESTORE STEM CELL OR PROGENITOR CELL FUNCTION AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2014-05-15 | — | — | WO | claimed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| EP-2828250-B1 | QUINAZOLINE COMPOUNDS AND THEIR USE IN THERAPY | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2021-03-10 | — | — | EP | disclosed |
| US-20140294764-A1 | COMPOUNDS AND COMPOSITIONS USED TO EPIGENETICALLY TRANSFORM CELLS AND METHODS RELATED THERETO | ISTITUTO PASTEUR - FONDAZIONE CENCI BOLOGNETTI (IT) | 2014-10-02 | — | — | US | disclosed |
| US-20140294764-A1 | COMPOUNDS AND COMPOSITIONS USED TO EPIGENETICALLY TRANSFORM CELLS AND METHODS RELATED THERETO | ISTITUTO PASTEUR - FONDAZIONE CENCI BOLOGNETTI (IT) | 2014-10-02 | — | — | US | disclosed |
| US-20140294764-A1 | COMPOUNDS AND COMPOSITIONS USED TO EPIGENETICALLY TRANSFORM CELLS AND METHODS RELATED THERETO | ISTITUTO PASTEUR - FONDAZIONE CENCI BOLOGNETTI (IT) | 2014-10-02 | — | — | US | disclosed |
| WO-2014074517-A1 | CELLULAR COMPOSITIONS USED TO RESTORE STEM CELL OR PROGENITOR CELL FUNCTION AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2014-05-15 | — | — | WO | disclosed |
| WO-2014074517-A1 | CELLULAR COMPOSITIONS USED TO RESTORE STEM CELL OR PROGENITOR CELL FUNCTION AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2014-05-15 | — | — | WO | disclosed |
| WO-2013140148-A1 | QUINAZOLINE COMPOUNDS AND THEIR USE IN THERAPY | IMPERIAL INNOVATIONS LIMITED (GB) | 2013-09-26 | — | — | WO | disclosed |
| WO-2013140148-A1 | QUINAZOLINE COMPOUNDS AND THEIR USE IN THERAPY | IMPERIAL INNOVATIONS LIMITED (GB) | 2013-09-26 | — | — | WO | disclosed |
| WO-2013070852-A2 | COMPOUNDS AND COMPOSITIONS USED TO EPIGENETICALLY TRANSFORM CELLS AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013070852-A2 | COMPOUNDS AND COMPOSITIONS USED TO EPIGENETICALLY TRANSFORM CELLS AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | EHMT2 2235/4885NSD2 3229/4885NSD3 2277/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | EHMT2 624/4885NSD2 3370/4885NSD3 1872/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | EHMT2 624/4885NSD2 3370/4885NSD3 1872/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | EHMT2 751/4885NSD2 1122/4885NSD3 1478/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | EHMT2 2637/4885NSD2 3404/4885NSD3 2018/4885 |
| US-20140294764-A1 | COMPOUNDS AND COMPOSITIONS USED TO EPIGENETICALLY TRANSFORM CELLS AND METHODS RELATED THERETO | BMI1, DNMT3L, DNMT3B | EHMT2 8/4885NSD2 265/4885NSD3 94/4885 |
| US-20150259649-A1 | CELLULAR COMPOSITIONS USED TO RESTORE STEM CELL OR PROGENITOR CELL FUNCTION AND METHODS RELATED THERETO | BMI1, DNMT1, DNMT3A | EHMT2 8/4885NSD2 1028/4885NSD3 277/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | EHMT2 691/4885NSD2 2084/4885NSD3 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.